Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee

Pediatric Blood and Cancer

Volumn 60, Issue 3, 2013, Pages 363-370

  Suganuma, Rie ^a   Wang, Larry L ^a   Sano, Hideki ^b   Naranjo, Arlene ^c   London, Wendy B ^d   Seeger, Robert C ^a   Hogarty, Michael D ^e   Gastier Foster, Julie M ^f   Look, A Thomas ^g   Park, Julie R ^h   Maris, John M ^e   Cohn, Susan L ⁱ   Amann, Gabriele ^j   Beiske, Klaus ^k   Cullinane, Catherine J ^l   d'Amore, Emanuele S G ^m   Gambini, Claudio ⁿ   Jarzembowski, Jason A ^o   Joshi, Vijay V ^p   Navarro, Samuel ^q   Peuchmaur, Michel ^r   Shimada, Hiroyuki ^a   more..

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f OHIO UNIVERSITY   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^m SAN BORTOLO HOSPITAL   (Italy)

ⁿ G GASLINI INSTITUTE   (Italy)

^o Children's Hospital of Wisconsin   (United States)

^p VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF VALENCIA   (Spain)

^r UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Genotype phenotype correlation; Immunohistochemistry; International Neuroblastoma Pathology Classification; MYCN; Neuroblastoma; Prognosis

Indexed keywords

ARTICLE; CANCER STAGING; CELL NUCLEUS; CHILD; CHILDHOOD CANCER; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MITOSIS; NEUROBLASTOMA; NUCLEOLUS; ONCOGENE C MYB; PHENOTYPE; PLOIDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA SYNTHESIS; TUMOR DIFFERENTIATION;

CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KAPLAN-MEIER ESTIMATE; MALE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; RESEARCH REPORT;

EID: 84872472525     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24238     Document Type: Article

References (36)

1. Evans AE, D'Angio GJ, Propert K, et al. Prognostic factors in neuroblastoma. Cancer 1987; 59: 1853-1859.
2. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
3. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Cancer 1971; 27: 374-378.
4. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999; 86: 349-363.
5. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer 1999; 86: 364-372.
6. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastoma correlates with advanced disease stage. Science 1984; 224: 1121-1124.
7. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 1985; 313: 1111-1116.
8. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11p deletions and outcome in neuroblastoma. N Engl J Med 2005; 353: 2243-2253.
9. Schwab M, Westermann F, Hero B, et al. Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet Oncol 2003; 4: 472-480.
10. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991; 9: 581-591.
11. Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995; 87: 1470-1476.
12. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. Cancer 2001; 92: 2699-2708.
13. Tornoczky T, Kalman E, Kajtar PG, et al. Large cell neuroblastoma: A distinct phenotype of neuroblastoma with aggressive clinical behavior. Cancer 2004; 100: 390-397.
14. Kobayashi C, Monforte-Munoz HL, Gerbing RB, et al. Enlarged and prominent nucleoli may be indicative of MYCN amplification: A study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Cancer 2005; 103: 174-180.
15. Thorner PS, Ho M, Chilton-MacNeill S, et al. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections. Am J Surg Pathol 2006; 30: 635-642.
16. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group study. J Clin Oncol 1998; 16: 1256-1264.
17. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-1173.
18. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stage I and II neuroblastoma treated with surgery as primary therapy: A Children's Cancer Group study. J Clin Oncol 2000; 18: 18-26.
19. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003; 8: 278-292.
20. Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: Report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009; 100: 1471-1482.
21. Ambros IM, Hata J, Joshi VV, et al. Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. Cancer 2002; 94: 1574-1583.
22. Heras A, Roach CM, Key ME. Enhanced polymer detection system for immunohistochemistry. Lab Invest 1995; 72: 165 (abstract).
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II: Analysis and Examples. Br J Cancer 1977; 35: 1-39.
25. Cohn SL, Look AT, Joshi VV, et al. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group Study. Cancer Res 1993; 55: 721-726.
26. Fabbretti G, Valenti C, Loda M, et al. N-myc gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma). Hum Pathol 1993; 24: 294-297.
27. Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 2000; 22: 197-205.
28. George RE, Variend S, Cullinane C, et al. Relationship between histopathological features, MYCN amplification, and prognosis: A UKCCSG study. Med Pediatr Oncol 2001; 36: 169-176.
29. Nakagawa A, Matsuoka K, Okita H, et al. Neuroblastomas with discordant genotype-phenotype relationship: Report of four cases with MYCN amplification and favorable histology. Pediatr Dev Pathol 2011; 14: 87-92.
30. Wenzel A, Cziepluch C, Hamann U, et al. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells. ENMO J 1991; 10: 3703-3712.
31. Kretzner L, Blackwood EM, Eisenman RN. Myc and Max proteins possess distinct transcriptional activities. Nature 1992; 359: 426-429.
32. Luscher B, Larsson LG. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: Function and regulation. Oncogene 1999; 18: 2955-2966.
33. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004-3016.
34. Bond VC, Wold B. Nucleolar localization of myc transcripts. Mol Cell Biol 1993; 13: 3221-3230.
35. Arabi A, Rustum C, Hallberg E, et al. Accumulation of c-Myc and proteasomes at the nucleoli of cells containing elevated c-Myc protein levels. J Cell Sci 2003; 116: 1707-1717.
36. Okamatsu C, London WB, Naranjo A, et al. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatr Blood Cancer 2009; 53: 563-569.